On 10th September, 2012 Delhi High Court gave an order while adjudicating a trademark dispute between Exide Industries Limited, the biggest storage battery producing company in India and Exide Corporation, a USA based company on the use of the ‘Exide’ name. In the decision court restrained Exide Corporation USA from using the trademark ‘Exide’ [...]
Versace’s medusa motif, the Vera Wang wedding dress, Louis Vuitton handbag – all these are products of applied intellectual creativity and skill in the fashion industry. No one doubts the tremendous value of intellectual capital to the creation and marketing of products in the fashion industry, be it high fashion or ready-to-wear. Yet many [...]
Do what really makes you happy Enjoy distractions Be kind to yourself Share your skills for happiness Mounting obligations and hectic schedules can make it all too easy to lose track. But whether it’s the little things in life that make you smile, or the joy of working toward a larger goal, focusing on [...]
Urgently Required – IP Associate at IIPTA, Delhi Centre Designation – IP Associate Number of openings – 2 Job Description – This job involves the under mentioned roles and responsibilities: Performing trademark, copyright, patent filing. Up taking lectures for trademarks, patent, copyright etc. in various professional programs and workshops conducted at IIPTA. Content preparation [...]
IIPTA is proud to invite you to the International Conference on Intellectual Property Rights organized by Associated Chamber of Commerce and Industry of India Associated Chamber of Commerce and Industry of India Indian Institute of Patent and Trademark Attorney Education Partner government of India Government of India Chief Guest Shri D. V. Prasad Joint [...]
Delhi High Courts rejected US based Parma major BMS (Bristol-Myers Squibb) appeal to ban India’s Ranbaxy Laboratories’ from launching generic version of Hepatitis –B drug named ‘Entecavir’. According to Indian patent law, the patent holders have 20 years of exclusive rights of marketing and impede competitors to launch low cost generic drug markets. ‘Entecavir’ [...]
